Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any early-onset non-syndromic cataract in which the cause of the disease is a mutation in the NHS gene.
Features include: Nuclear cataract, Severely reduced visual acuity, and Sutural cataract.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Nuclear cataract, Sutural cataract |
Age of onset: at birth.
NHS encodes NHS actin remodeling regulator (1,651 aa). May function in cell morphology by maintaining the integrity of the circumferential actin ring and controlling lamellipod formation. Highest expression in Artery Aorta (13.7 TPM) and Cervix Endocervix (13.1 TPM).
Cataract 40 is associated with mutations in the NHS gene on chromosome X.
NHS is classified as a druggable target with score 0.0.
Genetic testing for NHS is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for cataract 40.
231 publications have been identified in PubMed for cataract 40. Kisho has analyzed 26 by research type. Research spans Epidemiology / Natural History (54%), Clinical Trial Publication (23%), and Basic Science / Preclinical (8%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 14 | 54% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:51 PM UTC
Online Mendelian Inheritance in Man
Clinical study results
6 |
23% |
Laboratory research | 2 | 8% |
Other research | 1 | 4% |
Research summaries | 1 | 4% |
Patient case studies | 1 | 4% |
New treatment approaches | 1 | 4% |
Carter WC (2026). [PMID: 42102948](https://pubmed.ncbi.nlm.nih.gov/42102948/). *Am J Ophthalmol*. [Clinical Trial Publication]
Huang T (2026). [PMID: 41822754](https://pubmed.ncbi.nlm.nih.gov/41822754/). *Front Genet*. [Gene Therapy / Novel Therapeutics]
Mohankumar A (2026). [PMID: 37276317](https://pubmed.ncbi.nlm.nih.gov/37276317/). *Unknown Journal*. [Epidemiology / Natural History]
Kang JH (2025). [PMID: 40602475](https://pubmed.ncbi.nlm.nih.gov/40602475/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Yeoh R (2025). [PMID: 41523129](https://pubmed.ncbi.nlm.nih.gov/41523129/). *Taiwan J Ophthalmol*. [Review / Meta-Analysis]
Narayan A (2025). [PMID: 40707639](https://pubmed.ncbi.nlm.nih.gov/40707639/). *Eye (Lond)*. [Epidemiology / Natural History]
Huang T (2025). [PMID: 39994540](https://pubmed.ncbi.nlm.nih.gov/39994540/). *BMC Ophthalmol*. [Basic Science / Preclinical]
Ma M (2025). [PMID: 41054170](https://pubmed.ncbi.nlm.nih.gov/41054170/). *Medicine (Baltimore)*. [Epidemiology / Natural History]
Udomwech L (2025). [PMID: 40407556](https://pubmed.ncbi.nlm.nih.gov/40407556/). *Med Sci (Basel)*. [Other]
Alsusa M (2025). [PMID: 39748109](https://pubmed.ncbi.nlm.nih.gov/39748109/). *Eye (Lond)*. [Epidemiology / Natural History]